What do systematic reviews say?

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

The review found no eligible studies for this question.

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in new‐onset diabetes mellitus compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.93 [0.69, 1.26]
  13 studies · 2791 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in lymphoma/PTLD compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 2.47 [0.78, 7.86]
  8 studies · 2537 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Target of rapamycin inhibitors (TOR‐I) leads to lower tremor compared with calcineurin inhibitors (CNI): secondary outcomes (high certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.25 [0.15, 0.41]
  6 studies · 799 participants
  High

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 2983 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 579 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 843 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 5.26 [2.87, 9.63]
  4 studies · 593 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in death (all causes) compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 1.31 [0.87, 1.98]
  19 studies · 3618 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in graft loss censored for death compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 1.32 [0.96, 1.81]
  14 studies · 3277 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Target of rapamycin inhibitors (TOR‐I) probably leads to higher biopsy‐proven acute rejection compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 1.7 [1.32, 2.19]
  15 studies · 3309 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Target of rapamycin inhibitors (TOR‐I) leads to lower CMV infection compared with calcineurin inhibitors (CNI): main outcomes (high certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.43 [0.29, 0.63]
  13 studies · 2026 participants
  High

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Target of rapamycin inhibitors (TOR‐I) probably leads to higher adverse wound outcomes: all complications compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 2.56 [1.94, 3.36]
  12 studies · 1679 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in all malignancies compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.86 [0.5, 1.48]
  10 studies · 2584 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Target of rapamycin inhibitors (TOR‐I) probably leads to higher number needing to change treatment compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 2.42 [1.88, 3.11]
  14 studies · 3148 participants
  Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

The review found no eligible studies for this question.

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found